MedTrace Logo

Exploring and Establishment of Combined Extracorporeal Life Support(CELS) in Critically Ill Children

NCT03654287 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-05-08

No results posted yet for this study

Summary

Multiple organ failure (MODS) is still the leading cause of death in children in ICU. The treatment of MODS is mainly organ function monitoring and organ replacement therapy. Life support technology in vitro mainly includes mechanical ventilation, continuous renal replacement therapy (CRRT), non-biological artificial liver and extracorporeal membrane oxygenation technology (ECMO). However, critically ill patients who have multiple organ failure often require multiple organ support meanwhile. Combined extracorporeal life support (CELS) is still in its infancy to be applied in the treatment of critical illness due to nonstandard technology and theory without key breakthroughs and evidence-based medicine in the treatment of severe children organ failure.Solving the system problems supported by CELS can effectively reduce the mortality and disability rate of critically ill children and enhance health care in Shanghai, even across China.

Conditions

  • Sepsis
  • Critical Illness
  • MODS

Interventions

OTHER

Treatment

The CELS way to intervene severe sepsis and refractory shock

Sponsors & Collaborators

  • Shanghai Children's Hospital

    collaborator OTHER

  • Shanghai Children's Medical Center

    collaborator OTHER

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Guoping Lu

    lead OTHER

Principal Investigators

  • Guoping LU, doctor · Children's Hospital of Fundan University

Eligibility

Min Age
29 Days
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-30
Primary Completion
2020-10-30
Completion
2021-10-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03654287 on ClinicalTrials.gov